open access
In-transit sentinel lymph nodes predicted by F-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography
- Department of Nuclear Medicine Mersin University
- Department of General Surgery, Medical Faculty Mersin University
- Department of Pathology, Faculty of Medicine, Mersin University
open access
Abstract
Although the in-transit lymph node is a well-known issue in malignant melanoma, it is not documented sufficiently in breast cancer. In this case report an in-transit lymph node demonstrated by both PET/CT and sentinel lymph node mapping and diagnosed by pathology is reported.
Abstract
Although the in-transit lymph node is a well-known issue in malignant melanoma, it is not documented sufficiently in breast cancer. In this case report an in-transit lymph node demonstrated by both PET/CT and sentinel lymph node mapping and diagnosed by pathology is reported.
Keywords
in transit, sentinel, breast, pet, scintigraphy.
Title
In-transit sentinel lymph nodes predicted by F-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography
Journal
Issue
Article type
Clinical vignette
Pages
37-39
Published online
2019-01-31
Page views
789
Article views/downloads
480
DOI
10.5603/NMR.2019.0007
Pubmed
Bibliographic record
Nucl. Med. Rev 2019;22(1):37-39.
Keywords
in transit
sentinel
breast
pet
scintigraphy.
Authors
Zehra Pinar Koc
Pelin Özcan Kara
Ahmet Dağ
Ferah Tuncel Daloğlu
- Giuliano AE, Kirgan DM, Guenther JM, et al. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg. 1994; 220(3): 391–8; discussion 398.
- Keskek M, Balas S, Gokoz A, et al. Re-evaluation of axillary skip metastases in the era of sentinel lymph node biopsy in breast cancer. Surg Today. 2006; 36(12): 1047–1052.
- Lyman GH, Temin S, Edge SB, et al. American Society of Clinical Oncology Clinical Practice. Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2014; 32(13): 1365–1383.
- Galimberti V, Cole BF, Zurrida S, et al. International Breast Cancer Study Group Trial 23-01 investigators. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol. 2013; 14(4): 297–305.
- van Deurzen CHM, Borgstein PJ, van Diest PJ. In-transit lymph node metastases in breast cancer: a possible source of local recurrence after Sentinel Node procedure. J Clin Pathol. 2008; 61(12): 1314–1316.
- Vidal-Sicart S, Pons F, Fuertes S, et al. Is the identification of in-transit sentinel lymph nodes in malignant melanoma patients really necessary? Eur J Nucl Med Mol Imaging. 2004; 31(7): 945–949.
- Statius Muller MG, van Leeuwen PAM, van Diest PJ, et al. Pattern and incidence of first site recurrences following sentinel node procedure in melanoma patients. World J Surg. 2002; 26(12): 1405–1411.
- Cserni G, Cserni G, Cserni G, et al. European Working Group for Breast Screening Pathology. Estimating the overlap between sentinel lymph nodes and axillary node samples in breast cancer. Pathol Oncol Res. 1999; 5(2): 129–133.
- Kim T, Giuliano AE, Lyman GH. Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a metaanalysis. Cancer. 2006; 106(1): 4–16.
- Cserni G. Commentary on in-transit lymph node metastases in breast cancer: a possible source of local recurrence after Sentinel Node procedure. J Clin Pathol. 2008; 61(12): 1233–1235.